The essential serological targets you must include are a core set of autoantibodies that detect hallmark systemic autoimmune diseases. This foundation centers on antinuclear antibodies (ANAs) as the screening gateway, backed by confirmatory markers such as anti-dsDNA, anti-Sm, anti-SS-A/Ro, anti-SS-B/La, anti-Scl-70, anti-centromere, anti-Jo-1, Rheumatoid Factor (RF), anti-CCP, c-ANCA, and p-ANCA. These analytes, when built into a multi-analyte immunoassay panel using high-purity recombinant or native autoantigens, enable accurate differential diagnosis of Systemic Lupus Erythematosus (SLE), Sjögren’s syndrome, systemic sclerosis, polymyositis/dermatomyositis, rheumatoid arthritis, and ANCA-associated vasculitis.
A diagnostic panel covering systemic autoimmune disease must balance screening breadth with confirmatory depth. The bare-minimum combination of ANAs, the major ENA profile (SS-A/Ro, SS-B/La, Sm, RNP, Scl-70, Jo-1), dsDNA, RF, anti-CCP, and ANCA captures the most prevalent and clinically actionable markers. Your panel’s architecture will succeed only if each target is supported by robust, natively folded antigen raw materials that guarantee reproducible conformational epitope exposure.
The Core Targets That No Multi-Analyte Panel Can Omit
Your starting point must be the autoantibodies that map directly to the highest-incidence systemic autoimmune diseases. These are the non-negotiables for any IVD kit aspiring to clinical utility.
Systemic Lupus Erythematosus: dsDNA and Sm
Anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) are serological hallmarks of SLE. Anti-dsDNA is highly specific for SLE and correlates with disease activity, making kinetic monitoring valuable. Anti-Sm is less sensitive but nearly pathognomonic. Including both gives you the power to catch SLE at different stages—a requirement for any panel that wants to be taken seriously.
Sjögren’s Syndrome: SS-A/Ro and SS-B/La
Anti-SS-A/Ro and anti-SS-B/La antibodies define the serological profile of primary Sjögren’s syndrome, though they also appear in SLE. Anti-Ro is particularly critical for identifying the risk of neonatal lupus. These two targets together provide the necessary specificity to distinguish Sjögren’s from other connective tissue diseases when combined with clinical signs.
Rheumatoid Arthritis: RF and Anti-CCP
No systemic panel is complete without Rheumatoid Factor (IgM-RF) and anti-cyclic citrullinated peptide (anti-CCP). Anti-CCP offers superior specificity for rheumatoid arthritis and can appear years before clinical onset. RF provides sensitivity but is less specific; pairing them creates a powerful dual-marker strategy that covers early and established disease.
Systemic Vasculitis: ANCA
c-ANCA (targeting proteinase 3) and p-ANCA (targeting myeloperoxidase) are essential to identify ANCA-associated vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Missing these means you’d completely omit a critical category of systemic autoimmune diseases with high organ-damage potential.
Expanding the Core to Cover Systemic Sclerosis and Myopathies
While the primary reference lists the most fundamental targets, a truly comprehensive multi-analyte panel for systemic autoimmune diseases must also encompass markers for systemic sclerosis and idiopathic inflammatory myopathies. These connective tissue disorders are systemic by nature and frequently overlap.
Systemic Sclerosis: Scl-70 and Centromere Proteins
Anti-Scl-70 (DNA topoisomerase I) is tightly linked to diffuse cutaneous systemic sclerosis and internal organ involvement. Anti-centromere antibodies (often CENP-B) are associated with the limited cutaneous form. Incorporating both allows your panel to differentiate the major scleroderma subtypes, which have profoundly different prognoses.
Myositis Spectrum: Jo-1 and PM-Scl
Anti-Jo-1 (histidyl-tRNA synthetase) is a serological flag for anti-synthetase syndrome, a subset of polymyositis and dermatomyositis. Anti-PM-Scl helps identify overlap syndromes with scleroderma features. These targets convert a generic connective-tissue panel into one that can parse the myositis spectrum—a frequent source of diagnostic confusion.
The Screening Gateway: Why ANA Still Matters
Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) on HEp-2 cells remain the internationally recommended screening test. Your panel shouldn’t just identify individual specificities; it should mirror the clinical workflow where a positive ANA triggers reflex testing. Using high-purity recombinant antigens for the specific ENA profile ensures that the follow-up is precise, reducing false-negative results caused by poorly exposed linear epitopes.
Understanding the Trade-offs: Panel Design and Analytical Pitfalls
Including more targets adds clinical value but also introduces biological, analytical, and economic trade-offs that IVD manufacturers must navigate.
- Antigen format dictates sensitivity. Recombinant antigens expressed in eukaryotic systems preserve conformational epitopes needed for anti-Jo-1, anti-Scl-70, and anti-CCP. Bacterial expression or denatured proteins can create false-negative results, undermining panel credibility in real clinical evaluations.
- Panel size affects specificity. Each added analyte increases the chance of a false-positive result if cutoff algorithms aren’t stringently validated on well-characterized disease and healthy cohorts. Multiplex panels must be tuned so that positivity in a low-prevalence marker doesn’t distract from a high-specificity diagnosis.
- Regulatory and reimbursement realities. Commercial payers often reimburse only for medically necessary subsets. Designing panels that are too broad may lead to utilization pushback; too narrow, and they fail to compete as a true systemic autoimmune workup. You need a modular approach where core plus optional reflex cartridges align with testing guidelines.
Making the Right Choice for Your Diagnostic Panel
Your ultimate panel composition depends on your intended clinical setting and the diseases you aim to capture.
- If your primary focus is primary-care screening: Include a strong ANA IIF or ELISA screening step, then reflex to anti-dsDNA, anti-SS-A/Ro, RF, and anti-CCP. This catches the highest-volume systemic diseases without overwhelming the lab.
- If your primary focus is a comprehensive connective-tissue-disease workup: Build the panel around ANA, anti-dsDNA, Sm, RNP, SS-A/Ro, SS-B/La, Scl-70, centromere, Jo-1, PM-Scl, RF, and anti-CCP. Add c-ANCA and p-ANCA to detect vasculitis that often mimics connective-tissue presentations.
- If your primary focus is monitoring disease activity: Prioritize markers with known titer-to-disease correlations—anti-dsDNA for SLE flares, ANCA for vasculitis relapse, and anti-CCP for rheumatoid arthritis progression. Ensure your raw materials provide quantitative linear ranges suitable for serial monitoring chemistries.
The most successful multi-analyte immunoassay panels don’t simply list antibodies; they replicate the clinical reasoning pathway. By anchoring your design in these essential serological targets and validating them with high-quality, natively folded antigens, you give laboratories the diagnostic confidence they need to manage complex systemic autoimmune diseases.
Summary Table:
| Disease Category | Key Autoantibody Targets | Diagnostic & Clinical Utility |
|---|---|---|
| Systemic Lupus Erythematosus (SLE) | Anti-dsDNA, Anti-Sm | Specific diagnosis & disease activity monitoring |
| Sjögren’s Syndrome | Anti-SS-A/Ro, Anti-SS-B/La | Differential diagnosis & neonatal lupus risk assessment |
| Rheumatoid Arthritis (RA) | RF (IgM), Anti-CCP | Early detection, superior specificity & disease prognosis |
| Systemic Vasculitis | c-ANCA (PR3), p-ANCA (MPO) | Diagnostic identification of ANCA-associated vasculitides |
| Systemic Sclerosis | Anti-Scl-70, Anti-CENP-B | Scleroderma subtype differentiation (diffuse vs. limited) |
| Myositis Spectrum | Anti-Jo-1, Anti-PM-Scl | Parsing anti-synthetase and overlap syndromes |
Accelerate Your Autoimmune Assay Development with CamelBio
Building clinically reliable multi-analyte immunoassay panels demands high-purity, natively folded antigen raw materials that ensure reproducible conformational epitope exposure and linear analytical range.
CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Whether you are optimizing panel sensitivity, reducing cross-reactivity, or scaling production, our team is equipped to support your assay development goals.
Contact CamelBio today to request antigen samples and technical support!